TABLE 3.
Univariate analyses of potential predictors of biochemical failure and distant metastasis
| Biochemical failure
|
Distant metastasis
|
||||||
|---|---|---|---|---|---|---|---|
| ASTROa |
Nadir+2b |
||||||
| Covariate | No. of men | (5-year) | P | (5-Year) | P | (5-Year) | P |
| Age (years) | |||||||
| ≤ 68 | 894 | 29% | 20% | 4% | |||
| >68 | 939 | 29% | .9501 | 20% | .8251 | 3% | .2034 |
| T-category | |||||||
| T1–T2 | 1695 | 26% | 18% | 3% | |||
| T3–T4 | 138 | 58% | <.0001 | 45% | <.0001 | 12% | <.0001 |
| Gleason score | |||||||
| 2–6 | 1296 | 25% | 16% | 2% | |||
| 7 | 458 | 39% | 28% | 7% | |||
| 8–10 | 79 | 41% | <.0001 | 44% | <.0001 | 11% | <.0001 |
| iPSA (ng/mL) | |||||||
| <10 | 1087 | 25% | 13% | 2% | |||
| 10-<20 | 495 | 29% | 20% | 4% | |||
| ≥20 | 251 | 61% | <.0001 | 48% | <.0001 | 8% | <.0001 |
| Neoadjuvant/adjuvant AD | |||||||
| No | 1639 | 27% | 20% | 4% | |||
| Yes | 194 | 43% | <.0001 | 23% | <.0001 | 4% | .5193 |
| RT dose (Gy) | |||||||
| <74 | 668 | 37% | 24% | 5% | |||
| 74-<76 | 705 | 26% | 20% | 3% | |||
| ≥76 | 460 | 20% | <.0001 | 15% | .0523 | 3% | .2917 |
ASTRO indicates American Society of Therapeutic Radiology and Oncology; iPSA, initial pretreatment prostate-specific antigen level; AD, androgen deprivation; RT, radiotherapy; Gy, Gray.
a
ASTRO definition of biochemical failure: 3 consecutive rises in PSA, with BF backdated to midpoint between nadir and the first rise.8